PHILADELPHIA, Sept. 7, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude SkinPrep System for transdermal drug delivery, today announced that Patrick T. Mooney, M.D., CEO, President and Chairman of the Board of Echo Therapeutics will present at the Rodman & Renshaw Annual Global Investment Conference.
Dr. Mooney will make a corporate presentation to prospective corporate partners and investors on Monday, September 12th at 4:30 PM ET. The Company's presentation will be delivered at The Waldorf-Astoria Hotel in New York City.
About Echo Therapeutics
Echo is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.
For More Information:
Christine Olimpio
Director, Corporate Communications
(215) 717-4104
SOURCE Echo Therapeutics, Inc.
